Gazelle Parent, INC

Obsidian Therapeutics, Inc. announced the completion of its merger with Galera Therapeutics, Inc. and a $350 million private placement, bolstering its cash position to fund operations into late 2028.

Maria Fardis, a Director of Gazelle Parent, Inc., received 37,653 shares of common stock on August 3, 2026.

Deep Track Capital, along with affiliated entities, has reported beneficial ownership of 5.37% of Obsidian Therapeutics' common stock as of August 11, 2026.

Multiple Atlas Venture funds have collectively reported beneficial ownership of 7.3% of Obsidian Therapeutics, Inc. common stock as of August 3, 2026.

RA Capital Management and its affiliates have reported beneficial ownership of 9.7% of Obsidian Therapeutics' common stock as of August 3, 2026.

Novo Holdings A/S has reported acquiring a 5.1% stake in Obsidian Therapeutics, Inc., signaling a notable investment from a major life sciences focused firm.